Amgen (AMGN) PT Raised to $195 at Barclays

Go back to Amgen (AMGN) PT Raised to $195 at Barclays

Amgen (AMGN) PT Raised to $179 at Baird

July 27, 2018 8:48 AM EDT

Baird raised its price target on Amgen (NASDAQ: AMGN) to $179.00 (from $165.00) while maintaining a Neutral rating.

... More

Amgen (AMGN) PT Raised to $205 at Cowen Following 'Beat and Raise'

July 27, 2018 8:24 AM EDT

Cowen raised its price target on Amgen (NASDAQ: AMGN) to $205.00 (from $204.00) while maintaining a Outperform rating.

Analyst Phil Nadeau commented, "Amgen reported Q2 revenue of $6.06B (+4% Y/Y, vs. consensus of $5.73BE) and non-GAAP EPS of $3.83 (+17% Y/Y, vs. consensus of $3.54E). Amgen both... More

Amgen (AMGN) PT Raised to $194 at UBS

July 27, 2018 7:00 AM EDT

UBS raised its price target on Amgen (NASDAQ: AMGN) to $194.00 (from $180.00) while maintaining a Neutral rating.

... More

Amgen (AMGN) PT Raised to $210 at Piper Jaffray Following 2Q

July 27, 2018 6:45 AM EDT

Piper Jaffray raised its price target on Amgen (NASDAQ: AMGN) to $210.00 (from $190.00) while maintaining a Overweight rating following the company's 2Q earnings report. AMGN posted Q218 non-GAAP EPS of $3.83, well ahead of consensus $3.55. Upside was operationally driven as revenue beat handily (total revenue was... More

Options expected to be active: EA EXPE AMGN TLT

July 27, 2018 5:17 AM EDT

Options expected to be active: EA EXPE AMGN TLT

... More

Amgen profit beats Street view, will not raise prices again in 2018

July 26, 2018 4:16 PM EDT

By Michael Erman and Robin Respaut

(Reuters) - Amgen Inc (NASDAQ: AMGN) on Thursday reported a better-than-expected second quarter profit and raised its full-year earnings forecast, and its chief executive pledged not to raise drug prices again this year.

Amgen joined several drugmakers that have vowed to limit or delay price increases under intensifying pressure from the Trump administration to cut health care costs for U.S. consumers.

The world's largest biotechnology company also announced replacements for its head of research and development and retiring global commercial operations chief.

... More

Amgen (AMGN) Tops Q2 EPS by 29c

July 26, 2018 4:02 PM EDT

Amgen (NASDAQ: AMGN) reported Q2 EPS of $3.83, $0.29 better than the analyst estimate of $3.54. Revenue for the quarter came in at $6.06 billion versus the consensus estimate of $5.73 billion.

GUIDANCE:

Amgen sees FY2018 EPS of $13.30-$14.00, versus the consensus of $13.75. Amgen sees... More

Amgen (AMGN) call put ratio 1.42 calls to 1 put into EPS and outlook

July 26, 2018 2:29 PM EDT

Amgen (NASDAQ: AMGN) July weekly call option implied volatility is at 67, August is at 23; compared to its 52-week range of 16 to 31 into the expected release of Q2 today after the market close.

... More

Amgen (AMGN) weekly option implied volatility increases into EPS and outlook

July 26, 2018 5:19 AM EDT

Amgen (NASDAQ: AMGN) July weekly call option implied volatility is at 50, August is at 28; compared to its 52-week range of 16 to 31 into the expected release of Q2 after today after the market close.

... More

Amgen (AMGN) call put ratio 1 to 1 into Q2 and outlook

July 25, 2018 10:37 AM EDT

Amgen (NASDAQ: AMGN) July weekly call option implied volatility is at 49, August is at 28; compared to its 52-week range of 16 to 31 into the expected release of Q2 after the market close on July 26.

... More

Amgen (AMGN) weekly option implied volatility elevated into EPS and outlook

July 25, 2018 5:27 AM EDT

Amgen (NASDAQ: AMGN) July weekly call option implied volatility is at 44, August is at 23; compared to its 52-week range of 16 to 31 into the expected release of Q2 after the market close on July 26.

... More